Head-To-Head Comparison: iRadimed (NASDAQ:IRMD) and Enovis (NYSE:ENOV)

iRadimed (NASDAQ:IRMD) and Enovis (NYSE:ENOV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Risk and Volatility

iRadimed has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for iRadimed and Enovis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0	2	3	1	2.83
Enovis	1	1	10	0	2.75

iRadimed presently has a consensus price target of $120.00, suggesting a potential upside of 36.91%. Enovis has a consensus price target of $37.25, suggesting a potential upside of 86.92%. Given Enovis’ higher possible upside, analysts clearly believe Enovis is more favorable than iRadimed.

Profitability

This table compares iRadimed and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Enovis	-47.96%	12.03%	4.91%

Institutional & Insider Ownership

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares iRadimed and Enovis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81 million	13.38	$22.48 million	$1.79	48.97
Enovis	$2.25 billion	0.51	-$1.18 billion	($19.26)	-1.03

iRadimed has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Summary

iRadimed beats Enovis on 10 of the 15 factors compared between the two stocks.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.